Surgical and Chemotherapeutic Options for Urachal Carcinoma: Report of Ten Cases and Literature Review

Yazawa, Satoshi; Kikuchi, Eiji; Takeda, Toshikazu; Matsumoto, Kazuhiro; Miyajima, Akira; Nakagawa, Ken; Oya, Mototsugu
March 2012
Urologia Internationalis;Mar2012, Vol. 88 Issue 2, p209
Academic Journal
Objective: Several studies have associated urachal carcinoma with a poor prognosis, because the disease tends to be detected later as the patient is asymptomatic, there are few therapeutic options, and it has a high local recurrence rate. We review our experience with urachal carcinoma and discuss the role of surgical management and chemotherapeutic options. Patients and Methods: We reviewed the records of 10 cases with urachal carcinoma evaluated at Keio University Hospital from 1998 to 2009, and examine the surgical and chemotherapeutic options in the management of urachal carcinoma. Results: Median age was 55.0 years. Applying the TNM staging system, 1 case was in stage I, 4 cases in stage II, 4 cases in stage III, and 1 case was in stage IV. Nine cases were managed initially with surgery; 5 by partial cystectomy and 4 by total cystectomy. The median follow-up period was 3.5 years and the survival rate at 2 years was 87.5%. Six of the resected cases remain disease-free. Salvage chemotherapy was performed in 3 cases, and adjuvant chemotherapy was performed in 2 cases. Conclusions: We had 10 cases with urachal carcinoma. While there is still no standard chemotherapy combination, CPT-11 plus TS-1 produced stable disease in 1 case. Copyright © 2011 S. Karger AG, Basel


Related Articles

  • Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer. Racioppi, M.; D'Agostino, D.; Totaro, A.; Pinto, F.; Sacco, E.; D'Addessi, A.; Marangi, F.; Palermo, G.; Bassi, P.F. // Urologia Internationalis;Apr2012, Vol. 88 Issue 3, p249 

    The aim of the present paper was to review findings from the most relevant studies and to evaluate the value of current chemotherapy and surgery in advanced unresectable and metastatic bladder cancer. Studies were identified by searching the MEDLINE® and PubMed® databases up to 2011 using...

  • Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. Wolters, Mathias; Kramer, Mario; Becker, Jan; Christgen, Matthias; Nagele, Udo; Imkamp, Florian; Burchardt, Martin; Merseburger, Axel; Kuczyk, Markus; Bach, Thorsten; Gross, Andreas; Herrmann, Thomas // World Journal of Urology;Aug2011, Vol. 29 Issue 4, p429 

    Introduction: Exact pathological staging of bladder cancer is crucial for determination of further treatment. One limiting factor is the surgical 'incise and scatter' technique that might contribute to tumour recurrence. En bloc resection techniques are en emerging issue. We present initial...

  • Risk factors for brain metastases in surgically staged IIIA non-small cell lung cancer patients treated with surgery, radiotherapy and chemotherapy. Petrović, Marina; Ilić, Nevenka; Lončarević, Olivera; Čekerevac, Ivan; Lazić, Zorica; Novković, Ljiljana; Ćupurdija, Vojislav; Kostić, Gordana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Aug2011, Vol. 68 Issue 8, p643 

    Introduction/Aim. Lung cancer is a leading cause of mortality among patients with carcinomas. The aim of this study was to point out risk factors for brain metastases (BM) appearance in patients with IIIA (N2) stage of non- small cell lung cancer (NSCLC) treated with three-modal therapy....

  • Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Aoyama, Toru; Yoshikawa, Takaki; Miyagi, Yohei; Kameda, Yoichi; Shirai, Junya; Hayashi, Tsutomu; Cho, Haruhiko; Oshima, Takashi; Yukawa, Norio; Rino, Yasushi; Masuda, Munetaka; Tsuburaya, Akira // Surgery Today;Dec2013, Vol. 43 Issue 12, p1390 

    Purposes: The trastuzumab for Gastric Cancer study newly defined tumors that were positive for human epidermal receptor-2 (Her-2) and created a Her-2-oriented treatment strategy that is also applicable in the adjuvant setting for stage 2/3 cancers. However, there is currently no information...

  • PD-0016 TUMOR BUDDING IN COLORECTAL CANCER WITH REGARDS TO MISMATCH REPAIR STATUS – PROGNOSTIC VALUE? Karlberg, M.; Edler, D.; Hallström, M.; Ragnhammar, P.; Lenander, C. // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii11 

    No abstract available.

  • Prognostic Factors for Upper Urinary Tract Urothelial Carcinoma after Nephroureterectomy. Kuroda, Kenji; Asakuma, Junichi; Horiguchi, Akio; Tasaki, Shinsuke; Yoshii, Hidehiko; Sato, Akinori; Ito, Keiichi; Seguchi, Kenji; Sumitomo, Makoto; Asano, Tomohiko // Urologia Internationalis;Mar2012, Vol. 88 Issue 2, p225 

    Introduction: The purpose of this study was to evaluate prognostic factors for patients with upper urinary tract urothelial carcinoma (UUT-UC) after nephroureterectomy and to seek a better way of finding more favorable clinical results for these patients. Patients and Methods: We retrospectively...

  • Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. Kwon, Taekmin; Jeong, In; Lee, JungBok; Lee, Chunwoo; You, Dalsan; Hong, Bumsik; Hong, Jun; Ahn, Hanjong; Kim, Choung-Soo // Journal of Cancer Research & Clinical Oncology;Jan2015, Vol. 141 Issue 1, p169 

    Objectives: The role of adjuvant chemotherapy (AC) after radical cystectomy for bladder cancer remains unclear. This study evaluated the benefits of cisplatin-based AC plus surgery versus surgery alone in patients with bladder cancer. Materials and methods: The medical records of 746 patients...

  • Intravesical chemo-immunotherapy in non muscle invasive bladder cancer. LEOPARDO, D.; CECERE, S. C.; DI NAPOLI, M.; CAVALIERE, C.; PISANO, C.; STRIANO, S.; MARRA, L.; MENNA, L.; CLAUDIO, L.; PERDONÀ, S.; SETOLA, S.; BERRETTA, M.; FRANCO, R.; TAMBARO, R.; PIGNATA, S.; FACCHINI, G. // European Review for Medical & Pharmacological Sciences;Aug2013, Vol. 17 Issue 16, p2145 

    Non-Muscle-Invasive-Bladder-Cancer represents 75-85% of the new bladder cancer cases per year. Trans-uretral vesical resection is the milestone for diagnosis and therapy. After primary treatment, recurrence is frequent depending on the presence of several established risk factors: multiplicity,...

  • Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer. Hu, Huihui; Meng, Qian; Lei, Ting; Zhang, Man // Clinical & Experimental Medicine;Aug2015, Vol. 15 Issue 3, p361 

    Drug resistance and recurrence are the major obstacles to bladder cancer chemotherapy. Our laboratory had reported that nucleophosmin1 was one of the differentially expressed proteins between bladder cancer cell lines PUMC-91 and PUMC-91/1.0ADM based on 2D-PAGE proteomics approaches. In this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics